Breast cancer could be distinguished into different molecular subtypes: luminal-like (luminal A or B), HER2-enriched, and basal-like, which differ in biology, treatment response, patients’ survival, and clinical outcome. This evidence concerns the gene ERBB2 and breast carcinoma.